摘要
Dear Editor,Programmed cell death 1 ligand 1(PD-L1)has been used as a biomarker for immune checkpoint inhibitors(ICIs)which exert durable efficacy in non-small cell lung cancer(NSCLC).^(1,2)However,many PD-L1-high patients only marginally respond to,and PD-L1-low patients still benefit from,ICIs.^(3,4)
基金
supported by the Key Project of the National Natural Science Foundation of China(81830093)
the National Key Research and Development Program of China(2022YFA1103900,2020YFA0803300)
the CAMS Innovation Fund for Medical Sciences(CIFMS,2022-RC310-05,2021-RC310-003)
the CAMS Initiative for Innovative Medicine(2021-/2M-1-021,2022-12M-2-001,2021-1-/2M-012)
the National Natural Science Foundation of China(82073092,82273076).
